Vaginal rings for menopausal symptom relief

Drugs and Aging

Volumn 21, Issue 12, 2004, Pages 757-766

  Ballagh, Susan A ^a,b  

^a EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; ETONOGESTREL; EVATANE; FEMRING; MENORING; PIPERAZINE ESTRONE SULFATE; PROGESTERONE; SILASTIC;

BIOMEDICAL TECHNOLOGY ASSESSMENT; DRUG DELIVERY SYSTEM; DRUG INDICATION; ESTROGEN THERAPY; FIRST PASS EFFECT; HUMAN; MENOPAUSAL SYNDROME; MENOPAUSE; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; THROMBOEMBOLISM; THROMBOSIS; VAGINA;

ADMINISTRATION, INTRAVAGINAL; CONTRACEPTIVE DEVICES, FEMALE; ESTRADIOL; FEMALE; HUMANS; MENOPAUSE; PROGESTERONE; VAGINA;

EID: 7044226315     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421120-00001     Document Type: Review

References (64)

1. Macht DI. The absorption of drugs and poisons through the vagina. J Pharmacol Path 1918; 10: 509-22
2. Dziuk PJ, Cook B. Passage of steroids through silicone rubber. Endocrinology 1966; 78: 208-11
3. Mishell Jr DR, Talas M, Parlow AF, et al. Contraception by means of a silastic vaginal ring impregnated with medroxyprogesterone acetate. Am J Obstet Gynecol 1970 May 1; 107(1): 100-7
4. Roumen FJ, Dieben TO. Clinical acceptability of an ethylene-vinyl-acetate nonmedicated vaginal ring. Contraception 1999 Jan; 59(1): 59-62
5. Malcolm K, Woolfson D, Russell J, et al. Influence of silicone elastomer solubility and diffusivity on the in vitro release of drugs from intravaginal rings. J Control Release 2003 Jun 24; 90 (2): 217-25
6. Cicinelli E, Di Naro E, De Ziegler D, et al. Placement of the vaginal 17beta-estradiol tablets in the inner or outer one third of the vagina affects the preferential delivery of 17beta-estradiol toward the uterus or periurethral areas, thereby modifying efficacy and endometrial safety. Am J Obstet Gynecol 2003 Jul; 189 (1): 55-8
7. Sivin I, Mishell Jr DR, Victor A, et al. A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings: II. Subjective and objective measures of effects: an international comparative trial. Contraception 1981 Oct; 24 (4): 359-76
8. Summers PR. The vagina: vaginal anatomy. American Society for Coloscopy and Cervical Pathology [online]. Available from URL: http://www.asccp.org/edu/ practice/vagina/anatomy.shtml [Accessed 2004 Aug 11]
9. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women: a randomized controlled trial. Arterioscler Thromb Vasc Biol 1997 Nov; 17 (11): 3071-8
10. Lacut K, Oger E, Le Gal G, et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. Thromb Haemost 2003 Jul; 90 (1): 124-31
11. Caine YG, Bauer KA, Barzegar S, et al. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992 Oct 5; 68 (4): 392-5
12. Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, et al. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism: a review. Drug Saf 1998 Feb; 18 (2): 117-23
13. Castellsague J, Perez Gutthann S, Garcia Rodriguez LA. Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism: a review. Drug Saf 1998 Feb; 18 (2): 117-23.
14. Daly E, Vessey MP, Hawkins MM, et al. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet 1996; 348 (9033): 977-80
15. Grodstein F, Stampfer MJ, Goldhaber SZ, et al. Prospective study of exogenous hormones and risk of pulmonary embolism in women. Lancet 1996; 348 (9033): 983-7
16. Jick H, Derby LE, Wald Myers M, et al. Risk of hospital administration for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet 1996; 348 (9033): 981-3
17. Pérez-Gutthann S, Garcia Rodriguez LA, Castellsague J, et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. BMJ 1997; 314 (7083): 796-800
18. Varas-Lorenzo C, Garcia-Rodriguez LA, Cattaruzzi C, et al. Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. Am J Epidemiol. 1998 Feb 15; 147 (4): 387-90
19. Scarabin PY, Oger E, Plu-Bureau G, et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003 Aug 9; 362 (9382): 428-32
20. Goebelsmann U, Mashchak CA, Mishell Jr DR. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 1985 Apr 1; 151 (7): 868-77
21. Miles RA, Paulson RJ, Lobo RA, et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. Fertil Steril 1994 Sep; 62 (3): 485-90
22. Cicinelli E, Cignarelli M, Sabatelli S, et al. Plasma concentrations of progesterone are higher in the uterine artery than in the radial artery after vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women. Fertil Steril 1998 Mar; 69 (3): 471-3
23. Ballagh SA, Mishell Jr DR, Lacarra M, et al. A contraceptive vaginal ring releasing norethindrone acetate and ethinyl estradiol. Contraception 1994 Dec; 50 (6): 517-33
24. Ahotupa M, Rauramo I, Vasankari TJ, et al. Estrogen replacement therapy in combination with continuous intrauterine progestin administration reduces the amount of circulating oxidized LDL in postmenopausal women: dependence on the dose of progestin. Ann Med 2004; 36 (4): 278-84
25. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002 Jul 17; 288 (3): 321-33
26. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study [published erratum appears in Lancet 2003 Oct 4; 362 (9390): 1160]. Lancet 2003 Aug 9; 362 (9382): 419-27
27. Beral V. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study [published erratum appears in Lancet 2003 Oct 4; 362 (9390): 1160]. Lancet 2003 Aug 9; 362 (9382): 419-27
28. de Lignieres B, Dennerstein L, Backstrom T. Influence of route of administration of progesterone metabolism. Maturitas 1995 Apr; 21 (3): 251-7
29. Weisberg E, Fraser IS, Lacarra M, et al. Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring. Contraception 1997 Oct; 56 (4): 233-9
30. Passmore C, McNamee B, deVries T. Serum estradoil concentrations following single-dose administration of a novel estradiol acetate intravaginal ring (IVR) delivering 50, 75, and 100 μg/day estradiol in healthy postmenopausal women [abstract]. J Br Menopause Soc 2001; 7 Suppl. S3: 30
31. Weisberg E, Fraser IS, Mishell Jr DR, et al. The acceptability of a combined oestrogen/progestogen contraceptive vaginal ring. Contraception 1995 Jan; 51 (1): 39-44
32. Smith P. Estrogens and the urogenital tract. Studies on steroid hormone receptors and a clinical study on a new estradiol-releasing vaginal ring. Acta Obstet Gynecol Scand 1993; 72 Suppl. 157: 1-26
33. McKinney KA, Thompson W. A practical guide to prescribing hormone replacement therapy. Drugs 1998 Jul; 56 (1): 49-57
34. Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol 1987 May; 156 (5): 1332-4
35. Ryan PJ, Harrison R, Blake GM, et al. Compliance with hormone replacement therapy (HRT) after screening for post menopausal osteoporosis. Br J Obstet Gynaecol 1992 Apr; 99 (4): 325-8
36. Haney AF, Ballagh SA, Wysocki S. Evaluation of acceptance and satisfaction with the use of a vaginal ring delivery system in postmenopausal women [abstract]. Menopause 2003; 10 (6) 580
37. Buckler H, Al-Azzawi F, UK VR Multicentre Trial Group. The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women. BJOG 2003 Aug; 110 (8): 753-9
38. Menoring® prescribing information. Craigvon (North Ireland): Galen Holdings PLC, 2002
39. Woolfson AD, Elliott GRE, Gilligan CA, et al. Design of an intravaginal ring for the controlled delivery of 17β-estradiol as its 3-acetate ester. J Control Release 1999 Sep 20; 61 (3): 319-28
40. Al-Azzawi F, Buckler HM. United Kingdom Vaginal Ring Investigator Group. Comparison of a novel vaginal ring delivering estradiol acetate versus oral estradiol for relief of vasomotor menopausal symptoms. Climacteric 2003 Jun; 6 (2): 118-27
41. Willhite LA, O'Connell MB. Urogenital atrophy: prevention and treatment. Pharmacotherapy 2001 Apr; 21 (4): 464-80
42. Notelovitz M, Mattox JH. Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17beta-estradiol. Menopause 2000 Sep-Oct; 7 (5): 310-7
43. Speroff L. Efficacy and tolerability of a novel estradiol vaginal ring for relief of menopausal symptoms. Obstet Gynecol 2003 Oct; 102 (4): 823-34
44. Nash HA, Alvarez-Sanchez F, Mishell Jr DR, et al. Estradiol-delivering vaginal rings for hormone replacement therapy. Am J Obstet Gynecol 1999 Dec; 181 (6): 1400-6
45. Chullapram T, Song JY. Fraser IS. Medium-term follow-up of women with menorrhagia treated by rollerball endometrial ablation. Obstet Gynecol 1996 Jul; 88 (1): 71-6
46. Estring® prescribing information. Kalamazoo (MI): Pharmacia and Upjohn Company, 2003
47. Gabrielsson J, Wallenbeck I, Birgerson L. Pharmacokinetic data on estradiol in light of the estring concept: estradiol and estring pharmacokinetics. Acta Obstet Gynecol Scand Suppl 1996; 163: 26-31
48. Ginsburg ES, Walsh BW, Gao X, et al. The effect of acute ethanol ingestion on estrogen levels in postmenopausal women using transdermal estradiol. J Soc Gynecol Investig 1995 Jan-Feb; 2(1): 26-9
49. Henriksson L, Stjernquist M, Boquist L, et al. A one-year multicenter study of efficacy and safety of a continuous, low-dose, estradiol releasing vaginal ring (Estring) in postmenopausal women with symptoms and signs of urogenital aging. Am J Obstet Gynecol 1996 Jan; 174 (1 Pt 1): 85-92
50. Casper F, Petri E. Local treatment of urogenital atrophy with an estradiol-releasing vaginal ring: a comparative and a placebo-controlled multicenter study. Vaginal Ring Study Group. Int Urogynecol J Pelvic Floor Dysfunct 1999; 10 (3): 171-6
51. Lose G, Englev E. Oestradiol-releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms. BJOG 2000 Aug; 107 (8): 1029-34
52. Ayton RA, Darling GM, Murkies AL, et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy. Br J Obstet Gynaecol 1996 Apr; 103 (4): 351-8
53. Barentsen R, van de Weijer PH, Schram JH. Continuous low dose estradiol released from a vaginal ring versus estriol vaginal cream for urogenital atrophy. Eur J Obstet Gynecol Reprod Biol 1997 Jan; 71 (1): 73-80
54. Eriksen B. A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 1999 May; 180 (5): 1072-9
55. Pinkerton JV, Shifren JL, La Valleur J, et al. Influence of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women. Menopause 2003 Jan-Feb; 10 (1): 45-52
56. Archer DF. Low-dose hormone therapy for postmenopausal women. Clin Obstet Gynecol 2003 Jun; 46 (2): 317-24
57. Tourgeman DE, Boostanfar R, Chang L, et al. Is there evidence for preferential delivery of ovarian estradiol to the endometrium? Fertil Steril 2001; 75 (6): 1156-8
58. Maruo T, Mishell DR, Ben-Chetrit A, et al. Vaginal rings delivering progesterone and estradiol may be a new method of hormone replacement therapy. Fertil Steril 2002 Nov; 78 (5): 1010-6
59. Hamada AL, Maruo T, Samoto T, et al. Estradiol/progesterone-releasing vaginal rings for hormone replacement therapy in postmenopausal women. Gynecol Endocrinol 2003 Jun; 17 (3): 247-54
60. Landgren BM, Johannisson E, Masironi B, et al. Pharmacokinetic and pharmacodynamic effects of small doses of norethisterone released from vaginal rings continuously during 90 days. Contraception 1979 Mar; 19 (3): 253-71
61. Mishell Jr DR, Lumkin M, Jackanicz T. Initial clinical studies of intravaginal rings containing norethindrone and norgestrel. Contraception 1975 Sep; 12 (3): 253-60
62. Dieben TO, Roumen FJ, Apter D. Efficacy, cycle control, and user acceptability of a novel combined contraceptive vaginal ring. Obstet Gynecol 2002 Sep; 100 (3): 585-93
63. Jones RK, Darroch JE, Henshaw SK. Patterns in the socioeconomic characteristics of women obtaining abortions in 2000-2001. Perspect Sex Reprod Health 2002 Sep-Oct; 34 (5): 226-35
64. Massai R, Miranda P, Valdes P, et al. Preregistration study on the safety and contraceptive efficacy of a progesterone-releasing vaginal ring in Chilean nursing women. Contraception 1999 Jul; 60(1); 9-14